Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results for OREX
5.64
-0.23 (-3.92%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.60 - 5.86
52 week 3.11 - 7.82
Open 5.86
Vol / Avg. 1.80M/1.95M
Mkt cap 722.99M
P/E     -
Div/yield     -
EPS -0.34
Shares 123.46M
Beta 2.48
Inst. own 92%
May 6, 2015
Q1 2015 Orexigen Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 25, 2015
Orexigen Therapeutics Inc at RBC Healthcare Conference
Feb 25, 2015
Q4 2014 Orexigen Therapeutics Inc Earnings Release
Feb 25, 2015
Q4 2014 Orexigen Therapeutics Inc Earnings Call - Webcast
Feb 12, 2015
Orexigen Therapeutics Inc at Leerink Global Healthcare Conference
Jan 13, 2015
Orexigen Therapeutics Inc at JPMorgan Healthcare Conference
Dec 3, 2014
Orexigen Therapeutics Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 2.64% -67.59%
Operating margin 10.39% -54.99%
EBITD margin - -54.99%
Return on average assets 1.33% -19.09%
Return on average equity 12.41% -116.89%
Employees 50 -
CDP Score - -

Address

3344 N Torrey Pines Ct Ste 200
LA JOLLA, CA 92037-1024
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development and commercialization of a pharmaceutical product and the development of a product candidate for the treatment of obesity. Its combination product candidates for obesity are ND32 (formerly Contrave), which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. The Company has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The Company retains marketing rights for NB32 outside the United States, Canada and Mexico and worldwide marketing rights for Empatic. The Company is developing its product candidates for large markets traditionally served by primary care physicians.

Officers and directors

Eckard Weber M.D. Independent Chairman of the Board
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Joseph P. Hagan Acting Chief Financial Officer, Treasurer, Chief Business Officer
Age: 45
Bio & Compensation  - Reuters
Heather D. Turner Senior Vice President, General Counsel, Secretary
Age: 41
Bio & Compensation  - Reuters
Preston S. Klassen M.D. Senior Vice President, Head of Global Development
Age: 45
Bio & Compensation  - Reuters
Mark D. Booth Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 49
Bio & Compensation  - Reuters
Wendy L. Dixon Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Brian H. Dovey MBA Independent Director
Age: 73
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 49
Bio & Compensation  - Reuters